160 related articles for article (PubMed ID: 18546615)
1. SMRP and HE4 as biomarkers for ovarian carcinoma when used alone and in combination with CA125 and/or each other.
Hellstrom I; Hellstrom KE
Adv Exp Med Biol; 2008; 622():15-21. PubMed ID: 18546615
[TBL] [Abstract][Full Text] [Related]
2. HE4 and mesothelin: novel biomarkers of ovarian carcinoma in patients with pelvic masses.
Abdel-Azeez HA; Labib HA; Sharaf SM; Refai AN
Asian Pac J Cancer Prev; 2010; 11(1):111-6. PubMed ID: 20593939
[TBL] [Abstract][Full Text] [Related]
3. Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study.
Anderson GL; McIntosh M; Wu L; Barnett M; Goodman G; Thorpe JD; Bergan L; Thornquist MD; Scholler N; Kim N; O'Briant K; Drescher C; Urban N
J Natl Cancer Inst; 2010 Jan; 102(1):26-38. PubMed ID: 20042715
[TBL] [Abstract][Full Text] [Related]
4. Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125.
Shah CA; Lowe KA; Paley P; Wallace E; Anderson GL; McIntosh MW; Andersen MR; Scholler N; Bergan LA; Thorpe JD; Urban N; Drescher CW
Cancer Epidemiol Biomarkers Prev; 2009 May; 18(5):1365-72. PubMed ID: 19423517
[TBL] [Abstract][Full Text] [Related]
5. Effects of personal characteristics on serum CA125, mesothelin, and HE4 levels in healthy postmenopausal women at high-risk for ovarian cancer.
Lowe KA; Shah C; Wallace E; Anderson G; Paley P; McIntosh M; Andersen MR; Scholler N; Bergan L; Thorpe J; Urban N; Drescher CW
Cancer Epidemiol Biomarkers Prev; 2008 Sep; 17(9):2480-7. PubMed ID: 18768519
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the accuracy of serum human epididymis protein 4 in combination with CA125 for detecting ovarian cancer: a prospective case-control study in a Korean population.
Kim YM; Whang DH; Park J; Kim SH; Lee SW; Park HA; Ha M; Choi KH
Clin Chem Lab Med; 2011 Mar; 49(3):527-34. PubMed ID: 21320028
[TBL] [Abstract][Full Text] [Related]
7. Potential markers that complement expression of CA125 in epithelial ovarian cancer.
Rosen DG; Wang L; Atkinson JN; Yu Y; Lu KH; Diamandis EP; Hellstrom I; Mok SC; Liu J; Bast RC
Gynecol Oncol; 2005 Nov; 99(2):267-77. PubMed ID: 16061277
[TBL] [Abstract][Full Text] [Related]
8. The diagnostic accuracy of two human epididymis protein 4 (HE4) testing systems in combination with CA125 in the differential diagnosis of ovarian masses.
Lenhard M; Stieber P; Hertlein L; Kirschenhofer A; Fürst S; Mayr D; Nagel D; Hofmann K; Krocker K; Burges A
Clin Chem Lab Med; 2011 Sep; 49(12):2081-8. PubMed ID: 21923475
[TBL] [Abstract][Full Text] [Related]
9. Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus.
Moore RG; Brown AK; Miller MC; Badgwell D; Lu Z; Allard WJ; Granai CO; Bast RC; Lu K
Gynecol Oncol; 2008 Aug; 110(2):196-201. PubMed ID: 18495222
[TBL] [Abstract][Full Text] [Related]
10. HE4: a new potential early biomarker for the recurrence of ovarian cancer.
Anastasi E; Marchei GG; Viggiani V; Gennarini G; Frati L; Reale MG
Tumour Biol; 2010 Apr; 31(2):113-9. PubMed ID: 20358424
[TBL] [Abstract][Full Text] [Related]
11. HE4 as a biomarker for ovarian and endometrial cancer management.
Li J; Dowdy S; Tipton T; Podratz K; Lu WG; Xie X; Jiang SW
Expert Rev Mol Diagn; 2009 Sep; 9(6):555-66. PubMed ID: 19732003
[TBL] [Abstract][Full Text] [Related]
12. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass.
Moore RG; Brown AK; Miller MC; Skates S; Allard WJ; Verch T; Steinhoff M; Messerlian G; DiSilvestro P; Granai CO; Bast RC
Gynecol Oncol; 2008 Feb; 108(2):402-8. PubMed ID: 18061248
[TBL] [Abstract][Full Text] [Related]
13. [The values of serum human epididymis secretory protein 4 and CA(125) assay in the diagnosis of ovarian malignancy].
Dong L; Chang XH; Ye X; Zhu LR; Zhao Y; Tian L; Cheng HY; Li XP; Zhang H; Liao QP; Fu TY; Cheng YX; Cui H
Zhonghua Fu Chan Ke Za Zhi; 2008 Dec; 43(12):931-6. PubMed ID: 19134334
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic performances of HE4 and CA125 for the detection of ovarian cancer from patients with various gynecologic and non-gynecologic diseases.
Park Y; Lee JH; Hong DJ; Lee EY; Kim HS
Clin Biochem; 2011 Jul; 44(10-11):884-8. PubMed ID: 21549107
[TBL] [Abstract][Full Text] [Related]
15. Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment.
Badgwell D; Lu Z; Cole L; Fritsche H; Atkinson EN; Somers E; Allard J; Moore RG; Lu KH; Bast RC
Gynecol Oncol; 2007 Sep; 106(3):490-7. PubMed ID: 17532030
[TBL] [Abstract][Full Text] [Related]
16. Usefulness of serum HE4 in endometriotic cysts.
Montagnana M; Lippi G; Danese E; Franchi M; Guidi GC
Br J Cancer; 2009 Aug; 101(3):548. PubMed ID: 19513069
[No Abstract] [Full Text] [Related]
17. Designing early detection programs for ovarian cancer.
Hartge P
J Natl Cancer Inst; 2010 Jan; 102(1):3-4. PubMed ID: 20042718
[No Abstract] [Full Text] [Related]
18. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma.
Hellström I; Raycraft J; Hayden-Ledbetter M; Ledbetter JA; Schummer M; McIntosh M; Drescher C; Urban N; Hellström KE
Cancer Res; 2003 Jul; 63(13):3695-700. PubMed ID: 12839961
[TBL] [Abstract][Full Text] [Related]
19. HE4 in ovarian cancer: from discovery to clinical application.
Montagnana M; Danese E; Giudici S; Franchi M; Guidi GC; Plebani M; Lippi G
Adv Clin Chem; 2011; 55():1-20. PubMed ID: 22126021
[TBL] [Abstract][Full Text] [Related]
20. [The value of CA125 and LDH assays in assisting diagnosis of epithelial ovarian carcinoma].
Qie M; Peng Z; Cao Z; Tang Q; He B
Hua Xi Yi Ke Da Xue Xue Bao; 1996 Sep; 27(3):310-3. PubMed ID: 9389070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]